Group 1 - The Hong Kong Innovative Drug ETF (159567) closed with a gain of 3.62% on August 29, with a trading volume of 2.004 billion yuan [1] - The fund was established on January 3, 2024, with an annual management fee of 0.50% and a custody fee of 0.10% [1] - As of August 28, 2024, the fund's latest share count was 6.619 billion, with a total size of 6.126 billion yuan, reflecting an increase of 1574.08% in shares and 1521.35% in size year-to-date [1] Group 2 - The current fund manager is Ma Jun, who has managed the fund since its inception, achieving a return of 85.10% during the tenure [2] - The top holdings of the fund include Innovent Biologics, WuXi Biologics, BeiGene, and others, with significant weightings such as 9.52% for Innovent Biologics and 9.47% for WuXi Biologics [2] - The fund's recent trading activity shows a cumulative trading amount of 34.226 billion yuan over the last 20 trading days, averaging 1.711 billion yuan per day [1]

Core Insights - The Hang Seng Healthcare Index (HSHCI) has seen a strong increase of 2.89%, with notable gains from stocks such as Times Angel (06699) up 7.60% and WuXi Biologics (02269) up 6.77% [3] - The Hang Seng Healthcare ETF (513060) has also risen by 2.49%, with a recent price of 0.7 yuan, and a cumulative increase of 36.13% over the past three months [3] - The Hang Seng Hong Kong Stock Connect Innovative Drug Selection Index (HSSCPB) has surged by 3.31%, with significant contributions from WuXi Biologics (02269) and Innovent Biologics (01801) [5] Market Activity - The Hang Seng Healthcare ETF recorded a turnover of 20.42% and a trading volume of 1.543 billion yuan, indicating active market participation [3] - The Hong Kong Stock Connect Innovative Drug Selection ETF (520690) had a turnover of 26.45% and a trading volume of 90.36 million yuan, reflecting strong market engagement [5] Fundraising and Innovations - Several innovative drug companies in Hong Kong have initiated placement financing, with total fundraising ranging from hundreds of millions to over 2 billion HKD, primarily aimed at R&D and commercialization [6] - A team in China has successfully completed the world's first clinical trial using brain-machine interfaces for precise tumor boundary navigation during surgery, enhancing surgical quality and patient outcomes [6] Institutional Insights - The recent wave of placements indicates a core market demand for "funding sustainability" among innovative drug companies, with leading firms leveraging this to strengthen R&D and international expansion [7] - The integration of brain-machine interfaces and AI technologies is expected to enhance medical procedures and operational efficiencies in healthcare settings [7] ETF Performance - The Hang Seng Healthcare ETF has seen a significant increase in shares, with a growth of 163 million shares over the past week, ranking it among the top comparable funds [10] - The ETF has recorded a net inflow of 40.986 million yuan recently, accumulating a total of 107 million yuan over the past five trading days [11] - The ETF's financing net purchase has reached 2.6577 million yuan this month, with a total financing balance of 274 million yuan [12] Valuation Metrics - The Hang Seng Healthcare ETF's latest price-to-earnings ratio (PE-TTM) stands at 29.44, indicating a valuation below 87.52% of the historical range over the past three years [16] - The Hong Kong Stock Connect Innovative Drug Selection ETF has a PE-TTM of 28.71, also reflecting a low valuation compared to historical data [21]

Investment Insights - The report highlights that the current moment may represent an absolute return starting point for the liquor industry, particularly for baijiu, as fund holdings have dropped to 2017 levels and the food and beverage sector's overweight ratio has decreased significantly from its 2019 peak [2][6][8] - The report suggests that the liquor industry is regaining its cyclical characteristics, with a 72% valuation correction observed since February 2021, indicating a slow adjustment process [6][7] Liquor Industry Analysis - The report indicates that the adjustment process for the liquor industry involves several stages, including a decline in distributor profitability, a decrease in receivables, and a subsequent recovery in genuine demand [7][8] - It is anticipated that the current cycle will see absolute returns earlier than the previous cycle, with the report suggesting that the bottoming out of the cycle will occur when most distributors have cleared their inventories [7][8] Company-Specific Insights: Heng Rui Pharmaceutical - Heng Rui Pharmaceutical reported a total revenue of 15.76 billion yuan for the first half of 2025, marking a year-on-year increase of 15.88%, with a net profit of 4.45 billion yuan, up 29.67% [18][20] - The company has seen a significant increase in innovative drug sales, which accounted for 60.66% of total revenue, with a 21.80% year-on-year growth in innovative drug sales [18][20] - Heng Rui has established a robust pipeline with over 90 innovative products in clinical development, indicating strong potential for future growth [19][20] Company-Specific Insights: Jin Feng Technology - Jin Feng Technology achieved a revenue of 28.54 billion yuan in the first half of 2025, reflecting a 41.3% year-on-year increase, with a net profit of 1.49 billion yuan, up 7.3% [30][33] - The wind power equipment segment saw a significant revenue increase of 71.2%, with total delivery capacity reaching 10.64 GW, a 106.6% year-on-year growth [31][33] - The report projects an upward revision of net profit forecasts for 2025-2027, reflecting a positive outlook for the company's recovery in profitability [33] Company-Specific Insights: Mi Xue Group - Mi Xue Group reported a revenue of 14.875 billion yuan for the first half of 2025, a 39.3% increase year-on-year, with a net profit of 2.718 billion yuan, up 44.1% [4][28] - The company continues to expand its store network, with a total of 53,014 stores, focusing on both domestic and international markets [4][28] - The report emphasizes the company's strong growth potential in both domestic and overseas markets, particularly in Southeast Asia [4][28] Company-Specific Insights: Sanxiang Technology - Sanxiang Technology reported a revenue of 529 million yuan in the first half of 2025, a 22% increase year-on-year, with a net profit of 39.3 million yuan, up 89% [4][22] - The growth in domestic mainframe business significantly contributed to the revenue increase, driven by major clients such as Geely and BYD [22][23] - The report highlights the potential for steady expansion in the automotive industry, particularly in the context of the shift towards new energy and lightweight vehicles [22][23]

Group 1 - The Hong Kong Innovative Drug ETF (159567) closed down 1.26% on August 28, with a trading volume of 2.227 billion yuan [1] - The fund was established on January 3, 2024, with a management fee of 0.50% per year and a custody fee of 0.10% per year [1] - As of August 27, 2024, the fund's latest share count was 6.506 billion shares, with a total size of 6.134 billion yuan, reflecting a year-to-date increase of 1545.50% in shares and 1523.46% in size compared to December 31, 2023 [1] Group 2 - The current fund manager is Ma Jun, who has managed the fund since its inception, achieving a return of 88.56% during the tenure [2] - The top holdings of the fund include Innovent Biologics (9.52%), WuXi Biologics (9.47%), BeiGene (8.73%), and others, with their respective market values and share counts detailed [2] - The fund's liquidity is strong, with a cumulative trading amount of 35.359 billion yuan over the last 20 trading days, averaging 1.768 billion yuan per day [1][2]

来源：市场资讯 至于连日有好表现之中港股市昨日均有所整调。A股方面，上综指及深成指均以全日最低位收市，前者 跌1.76%，报3,800点，后者则早段曾升1.54%，惟午后由升转跌，最终收报12,295点，下跌1.43%，不过 成交持续活跃，达到3.17万亿元人民币。港股表现亦有所转弱，恒指早段曾升近130点，不过午后A股下 挫，恒指亦由升转跌，其后跌幅更进一步扩大至384点，最终收报25,201点，下跌323点或1.3%，连跌第 二个交易日，科指亦跌1.5%，收报5,697点，全日成交显著增加至3,714亿元。成份股跌多升少，当中以 华润万象(01209.HK)表现最差，急挫超过9%，另个别医药股跌势显著，石药集团(01093.HK)及翰森制 药(03692.HK)分别下跌6.4%及5.7%，科技股亦有沽压，$美团-W(HK3690)及快手(01024.HK)均跌超过 3%。上升成份股中则以农夫山泉(09633.HK)表现最佳，升超过7%，公用股如中电(00002.HK)及煤气 (00003.HK)亦靠稳。 由于美团公布之业绩远逊预期，股价今日料会有较大沽压，今日新加坡黑期亦已回落至25,000点之下， 预期 ...

Group 1: Domestic Innovative Drugs - The clinical trial HARMONi-A for AK112, a core product of Kangfang Biotech, shows statistically significant overall survival (OS) benefits for second-line EGFR mutation non-small cell lung cancer (2L EGFRm NSCLC) [1] - AK112 has initiated 13 registrational/Phase III clinical studies globally, covering multiple high-incidence cancers such as lung cancer, cholangiocarcinoma, and triple-negative breast cancer, indicating its broad clinical potential [1] - Over 40 Chinese studies have been selected for presentation at the 2025 World Lung Cancer Conference (WCLC) in Barcelona, highlighting the increasing international recognition of domestic research [1] Group 2: Industry Performance - Fosun Pharma reported a revenue of 19.514 billion RMB and a net profit of 1.702 billion RMB for the first half of 2025, with innovative drug revenue exceeding 4.3 billion RMB, a year-on-year increase of 14.26% [2] - The operating cash flow for Fosun Pharma reached 2.134 billion RMB, up 11.90% year-on-year, while the company continues to optimize its asset structure by disposing of non-core assets totaling over 2 billion RMB since the beginning of 2025 [2] - As of August 28, 2025, the Hong Kong Innovation Drug Index fell by 2.17%, but the Hong Kong Innovation Drug ETF saw a 5.62% increase over the past month, with the top ten weighted stocks accounting for 70.59% of the index [2] Group 3: Financing and Market Trends - As of August 27, 2025, the latest financing buy-in for the Hong Kong Innovation Drug ETF was 761 million RMB, with a net inflow of 191 million RMB [3] - The global pharmaceutical transaction volume reached 456 deals in the first half of 2025, a 32% year-on-year increase, with a total transaction value of 130.4 billion USD, up 58% year-on-year, indicating growing recognition of Chinese enterprises in global innovative drugs [3] - The approval time for innovative drug clinical trials has been shortened to 30 working days, further promoting industry recovery [3]

证券研究报告 医药生物 | 化学制药 港股|公司点评报告 hyzqdatemark 2025 年 08 月 28 日 证券分析师 刘闯 SAC：S1350524030002 liuchuang@huayuanstock.com 市场表现： | 基本数据 | 2025 | 年 | 08 月 27 | | 日 | | --- | --- | --- | --- | --- | --- | | 收盘价（港元） | | | | 35.52 | | | 一年内最高/最低（港 | | | 39.76/15.96 | | | | 元） | | | | | | | 总市值（百万港元） | | | 215,078.93 | | | | 流通市值（百万港元） | | | 215,078.93 | | | | 资产负债率（%） | | | | 11.33 | | | 资料来源：聚源数据 | | | | | | 翰森制药(03692.HK) 投资评级： 买入（维持） ——创新收入高速增长，BD 收入有望贡献常态化增量 投资要点： 风险提示：临床研发失败风险，竞争格局恶化风险、销售不及预期风险等。 | 盈利预测与估值（人民币） | | ...

Market Performance - The Hang Seng Healthcare Index (HSHCI) decreased by 1.23% as of August 28, 2025, with mixed performance among constituent stocks [3] - The Hang Seng Medical ETF (513060) fell by 1.15%, with a latest price of 0.69 yuan, but showed a 6.26% increase over the past month, ranking in the top third among comparable funds [3] - The Hang Seng Hong Kong Stock Connect Innovative Drug Selection Index (HSSCPB) dropped by 1.02%, with the Hong Kong Innovative Drug Selection ETF (520690) down by 0.81% to 0.98 yuan [4] Company Highlights - Innovent Biologics reported a 50.6% year-on-year revenue increase to 5.95 billion yuan for the first half of 2025, achieving a gross margin of 86% and a net profit of 830 million yuan, driven by pipeline expansion in oncology and new product launches [4] - The company has over 2 billion USD in cash reserves to support future innovation pipeline advancements [4] Policy and Industry Developments - The Ministry of Commerce and Jiangsu Provincial Government issued a plan to enhance the biopharmaceutical industry in Jiangsu Free Trade Zone by 2030, focusing on large molecule biologics, cell and gene therapy, and innovative medical devices [5] - Recent market pressure on the pharmaceutical sector was noted, with the Hang Seng Healthcare Index dropping over 2.1%, influenced by U.S. tariff proposals on imported drugs that could disrupt the global pharmaceutical industry [5] Analyst Insights - Analysts suggest that the recent decline in the Hong Kong pharmaceutical sector is a short-term fluctuation and does not alter the long-term industry outlook, with ongoing favorable policies expected to drive more cross-border business development transactions [6] - The Chinese innovative drug assets are gaining international recognition, presenting structural opportunities in the medium to long term [6] ETF Performance and Metrics - The Hang Seng Medical ETF has seen a significant increase in scale by 46.87 million yuan this month, ranking in the top third among comparable funds [8] - The ETF's share count increased by 92.5 million shares over the past week, also ranking in the top third [9] - The ETF recorded a net inflow of 74.96 million yuan recently, with a total of 65.92 million yuan accumulated over the last five trading days [10] - The ETF's financing net purchase reached 2.5072 million yuan this month, with a financing balance of 268 million yuan [11] Risk and Return Metrics - The Hang Seng Medical ETF has achieved a 48.60% net value increase over the past two years, with a maximum monthly return of 28.34% since inception [11] - The ETF's Sharpe ratio for the past year is 2.41, indicating strong risk-adjusted returns [12] - The ETF has the lowest relative drawdown among comparable funds, with a drawdown of 0.63% year-to-date [13] Valuation Insights - The latest price-to-earnings ratio (PE-TTM) for the Hang Seng Medical ETF is 30.9, which is below the historical average, indicating a potentially undervalued position [15]

Market Overview - US stock indices experienced slight gains overnight, while the China concept index fell by 2.58% [1] - Hong Kong stock indices opened lower, with the Hang Seng Index down by 0.68%, the National Index down by 0.86%, and the Hang Seng Tech Index down by 0.99% [1] Company Performance - Major technology stocks mostly declined, with Meituan dropping nearly 10% post-earnings, Alibaba down nearly 2%, and JD.com down by 1% [1] - Tencent and Baidu saw slight declines, while NetEase increased by approximately 1% [1] - New energy vehicle stocks generally fell, with BYD down by 1.3% and "NIO" experiencing significant losses [1] Sector Movements - Insurance stocks, brain-computer interface concept stocks, photovoltaic stocks, Tesla-related stocks, and software stocks all saw declines [1] - Conversely, the biopharmaceutical sector became active again, with Innovent Biologics rising over 4%, and Fosun Pharma, Hansoh Pharmaceutical, and WuXi AppTec also showing gains [1] - Gold stocks generally increased, with Shandong Gold rising over 2% [1] - Gambling stocks, oil stocks, and semiconductor stocks mostly experienced upward movement [1]

Core Insights - The article discusses various economic indicators and market movements, highlighting the performance of major stock indices and commodities, as well as significant geopolitical developments affecting trade and investment [3][4][10]. Market Performance - U.S. stock indices experienced slight gains, with the Dow Jones up 0.32%, S&P 500 rising 0.24%, and Nasdaq increasing by 0.2% [4]. - European indices showed mixed results, with Germany's DAX30 down 0.44% and the UK FTSE 100 down 0.11%, while the Euro Stoxx 50 rose by 0.17% [4]. - Hong Kong's Hang Seng Index opened higher but closed down 1.27%, with significant trading volume of 371.37 billion HKD [5]. - A-shares saw a decline, with the Shanghai Composite Index down 1.76% and total trading volume reaching 3.17 trillion CNY, an increase of 486.5 billion CNY from the previous day [6]. Commodity Prices - Gold prices increased by 0.11%, closing at 3,397.46 USD per ounce, while silver saw a slight decrease of 0.04% [7]. - WTI crude oil rose by 0.79% to 63.65 USD per barrel, and Brent crude oil increased by 0.61% to 67.16 USD per barrel, driven by a reduction in U.S. oil inventories [7][10]. Geopolitical Developments - The U.S. administration is considering a 25% tariff reduction for India if it ceases oil purchases from Russia, indicating potential shifts in trade policies [10]. - The European Union is reportedly moving towards eliminating tariffs on U.S. industrial products, aligning with U.S. trade demands [10]. - The U.S. has resumed oil imports from Venezuela, marking a significant development in energy trade relations [12]. Corporate News - Nvidia reported better-than-expected earnings but provided a somewhat subdued revenue outlook, announcing a 60 billion USD share buyback plan [12]. - The Chinese tech sector faced declines, with major companies like JD.com and electric vehicle manufacturers experiencing significant stock price drops [4][5].